Baker MR.

ALS-dying forward, backward or outward?

Nature Reviews Neurology 2014, 10(11), 660-660

Copyright:

This is the author’s accepted manuscript of a letter published in its final definitive form by Nature Publishing Group, 2014.

DOI link to article:

http://dx.doi.org/10.1038/nrneurol.2013.221-c1

Date deposited:

02/06/2016
Heiko Braak and colleagues (Amyotrophic lateral sclerosis—a model of corticofugal axonal spread. Nature Rev. Neur. 9, 708–714; 2013) present impressively detailed evidence in support of corticofugal spread—also known as the ‘dying-forward’ model of neurodegeneration, first proposed by Eisen and Weber in amyotrophic lateral sclerosis (ALS). Here, I propose a refinement that integrates both the ‘dying-forward’ and ‘dying-back’ models: the corticofugal synaptopathy, or, ‘dying-outward’ hypothesis.

In any model of ALS, a number of fundamental features have to be reconciled: First, degenerative changes occur primarily in anterior horn cells and brainstem motoneurons that receive monosynaptic connections from motor cortex, and in the corticospinal tract neurons within primary motor cortex. Second, in some variants of ALS, the disease only affects the corticospinal tract neurons, whereas in other variants, it only affects anterior horn cells, or affects corticospinal tract neurons only very late in the disease. Third, ALS progresses contiguously between spinal, brainstem and cortical regions, in what has been termed a ‘prion-like’ pattern. Fourth, cortical areas involved late in the disease are linked via long-range synaptic connections. Last, humans are the only species affected by sporadic ALS and only nonhuman primate models of ALS have recapitulated features of the disease observed in humans.

An important component of the corticofugal model is the axonal transport hypothesis, which identifies the importance of long-range axonal connections in disease propagation, but overlooks the synapse—the very reason for the existence of such connections. Not only does the developing synapse, or growth cone, function independently but there is also evidence that synaptic autonomy continues into adulthood. For example, synaptic prion-like proteins maintain activity-dependent changes in synaptic efficacy independently of nuclear transcription within neuronal somata. Furthermore, mitochondria, essential for calcium buffering and energy, are maintained autonomously within the presynaptic and postsynaptic compartments. Such autonomy permits efficient long-distance neuronal communication, but there is a trade-off: the lysosomal housekeeping processes responsible for recycling biomolecules, organelles and cellular debris located within the distant soma function less efficiently. Consequently, abnormal conformational changes in prion-like proteins can replicate and propagate without control and dysfunctional mitochondria accumulate. The longer the axon and the larger the synapse, the more likely this autonomous process is to malfunction, hence the susceptibility of the monosynaptic cortico-motoneuronal synapse at the onset of ALS in man.

The cortico-motoneuronal synapse is a feature that distinguishes primates from other mammalian species, and the number of corticomotoneuronal synapses and length of axons in the corticospinal tract that distinguish humans from nonhuman primates. Mutations in mitochondrial DNA have been implicated in motor neuron diseases and ALS, and there is increasing evidence that the interaction between pathological synaptic mitochondria and synaptic prion proteins leads to neurodegeneration. The cortico-motoneuronal synapse, therefore, is not only pivotal as the link between the corticospinal tract and anterior horn cells, but also as the site of disease propagation in ALS.
tract and anterior horn cells but also; because of its vulnerability, it is an efficient nidus for neurodegeneration. Consequently, biomarkers that can detect changes in the integrity of the cortico-motoneuronal synapse should be able to identify the very earliest stages of ALS, enabling early disease-modifying therapeutic interventions at a stage when they can make a significant impact on survival in this dreadful disease.

Mark R. Baker
Institute of Neuroscience, Henry Wellcome Building, The Medical School, Newcastle University, Framlington Place, Newcastle upon Tyne NE2 4HH, UK Correspondence to: Mark.Baker@newcastle.ac.uk


**Competing interests:** The author declares no competing interests

**References**


